CAR T-CELL THERAPY

The CYAD-101-002 trial may resume after the FDA lifted the partial clinical hold to evaluate risk to study patients with metastatic colorectal cancer.

Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.

Bruce Feinberg, DO, discusses a survey researching chimeric antigen receptor T-cell therapy’s growing usage by community oncologists for diffuse large B-cell lymphoma.

Manali Kamdar, MD, discusses data from the 2 clinical trials that supported the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma.

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

The FDA has granted approval lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma, with specific indications for patients with relapsed or refractory disease.

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.

In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.

Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.

Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.

In preclinical study, researchers have identifies anti-TIGIT therapy as a potentially effective strategy for improving remission rates in patients with non-Hodgkin lymphoma after chimeric antigen receptor T-cell therapy.

In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.

Investigators of the phase 1/2 IMAGINE study, evaluating MT-101 in patients with refractory or relapsed peripheral T-cell lymphoma, have dosed its first patient.

Steven M. Albelda, MD, discusses the limited successes of CAR T cells in solid tumors.

An analysis of the ZUMA-5 and ELARA shows that the 2 CAR T-cell therapies, axicabtagene ciloleucel, and tisagenlecleucel have similar efficacy.

Lori A. Leslie, MD, discusses the impact that brexucabtagene autoleucel had on the treatment landscape for patients with relapsed or refractory mantle cell lymphoma.

Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.

Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.

Results from the phase 2 CARITUDE-2 trial of ciltacabtagene autoleucel in patients with multiple myeloma signaled that a 1 infusion can achieve deep responses.

Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.

In patients with relapsed/refractory large B-cell lymphoma, the chimeric antigen receptor T-cell agent, lisocabtagene maraleucel demonstrated durable responses.

Robert J. Soiffer, MD, discusses how the role of transplantation is evolving with the availability of chimeric antigen receptor T-cell agents.

Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.

Chimeric antigen receptor T-cell therapy showed early efficacy and a tolerable safety profile with or without an mRNA vaccine in a phase 1 clinical trial.

CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.

Preclinical research indicates that anti-mesothelin chimeric antigen receptor T cells may be more effective than gavocabtagene autoleucel in mesothelin-expressing tumors.

Prolonged periods of radiographic and clinical improvement in children and young adults with H3K27M diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas has been shown with GD2-directed chimeric antigen receptor T cells.

In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.

A phase 1 trial which will evaluate the safety and efficacy of chimeric antigen receptor T-cell therapy in ovarian cancer has begun.